Clinical Trial: LONG-TERM FOLLOW-UP OF OSIMERTINIB IN COMBINATION WITH PLATINUM AND PEMETREXED IN PATIENTS WITH PREVIOUSLY UNTREATED EGFR-MUTATED ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (THE OPAL STUDY): (NEJ032D) (Japan)

Tokyo, March 4 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060812) titled 'LONG-TERM FOLLOW-UP OF OSIMERTINIB IN COMBINATION WITH PLATINUM AND PEMETREXED IN PATIENTS WITH PREVIOUSLY UNTREATED EGFR-MUTATED ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (THE OPAL STUDY): (NEJ032D)' on March 4.

Study Type: Observational

Primary Sponsor: Institute - North East Japan Study Group

Condition: Condition - previously untreated EGFR-mutated advanced non-squamous NSCLC Classification by malignancy - Malignancy Genomic information - NO

Objective: Narrative objectives1 - We aim to conduct a long-term follow-up data analysis of the phase II OPAL trial, which evaluated osimertinib plus platinum-based...